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Background: Assessing risk of future exacerbations is an important component in COPD 
management. History of exacerbation is a strong and independent predictor of future exacerba-
tions, and the criterion of $2 nonhospitalized or $1 hospitalized exacerbation is often used to 
identify high-risk patients in whom therapy should be intensified. However, other factors or 
“treatable traits” also contribute to risk of exacerbation.
Objective: The objective of the study was to develop and externally validate a novel clinical 
prediction model for risk of hospitalized COPD exacerbations based on both exacerbation his-
tory and treatable traits.
Patients and methods: A total of 237 patients from the COPD Registry of Changi General 
Hospital, Singapore, aged 75±9 years and with mean post-bronchodilator FEV
1
 60%±20% 
predicted, formed the derivation cohort. Hospitalized exacerbation rate was modeled using 
zero-inflated negative binomial regression. Calibration was assessed by graphically comparing 
the agreement between predicted and observed annual hospitalized exacerbation rates. Pre-
dictive (discriminative) accuracy of the model for identifying high-risk patients (defined as 
experiencing $1 hospitalized exacerbations) was assessed with area under the curve (AUC) and 
receiver operating characteristics analyses, and compared to other existing risk indices. We exter-
nally validated the prediction model using a multicenter dataset comprising 419 COPD patients.
Results: The final model included hospitalized exacerbation rate in the previous year, history 
of acute invasive/noninvasive ventilation, coronary artery disease, bronchiectasis, and sputum 
nontuberculous mycobacteria isolation. There was excellent agreement between predicted and 
observed annual hospitalized exacerbation rates. AUC was 0.789 indicating good discriminative 
accuracy, and was significantly higher than the AUC of the Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) risk assessment criterion (history of $1 hospitalized exacerbation in 
the previous year) and the age, dyspnea, and obstruction index. When applied to the independent 
multicenter validation cohort, the model was well-calibrated and discrimination was good.
Conclusion: We have derived and externally validated a novel risk prediction model for COPD 
hospitalizations which outperforms several other risk indices. Our model incorporates several treat-
able traits which can be targeted for intervention to reduce risk of future hospitalized exacerbations.
Keywords: exacerbations, clinical prediction model, risk assessment
Introduction
COPD exacerbations are associated with high healthcare costs,1 reduced quality of 
life,2,3 accelerated lung function decline,4 and excess mortality.5 Hence, assessing 
future risk of exacerbation is an important component in current COPD management.6 
History of exacerbation in the previous year, either $2 nonhospitalized or $1 leading to 
hospital admission, is often used to identify high-risk patients in whom bronchodilator 
or inhaled steroid therapy should be intensified.6 This approach is based on history 
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of exacerbation being a strong and consistent predictor of 
future exacerbations,7 and is simple to use in clinical practice.
There are several limitations of using history of exac-
erbation alone to assess risk. First, exacerbations are het-
erogeneous8 and multiple risk factors besides history of 
exacerbation may predispose to subsequent exacerbation 
such as comorbidities, inflammatory phenotype, infection, 
smoking, low body mass index (BMI), and lung function.9 
Whether inclusion of other factors (also known as “treatable 
traits”)10 can improve the predictive accuracy for future exac-
erbations is unknown. Second, a significant subset of COPD 
patients may exacerbate without a history of exacerbation in 
the past year.11 In such patients, exacerbation risk is not accu-
rately predicted by history of exacerbation. Preemptive risk 
assessment – using variables which are independent of the 
occurrence of the first exacerbation – may trigger interven-
tions to mitigate occurrence of the first exacerbation and its 
associated adverse sequelae which may be irreversible such 
as accelerated lung function decline and mortality.4,5 Third, 
using $1 hospitalized or $2 nonhospitalized exacerbations 
in the past year to stratify risk is problematic because the opti-
mal threshold for dichotomizing risk is not known,7,11,12 and 
probably varies depending on the patient and health system 
factors. More importantly, annual exacerbation rate occurs 
as a gradient with a range of possible values, and dichoto-
mizing risk based on a predetermined cut-point ignores risk 
differences falling outside the cut-point that might still be 
clinically relevant. For example, a patient who has had five 
exacerbations in the past year clearly has worse prognosis and 
needs to be managed differently compared to an individual 
who has had two, but both would be classified as high-risk 
if using a threshold of $2 exacerbations.
Here, our aim was to derive a model for predicting risk 
of hospitalized COPD exacerbations which uses multiple 
clinically-relevant parameters and is capable of stratifying 
patients along a gradient of risk. We compared the predictive 
accuracy of the model to the GOLD risk assessment criterion 
(history of $1 exacerbation leading to hospitalization in the 
previous year) and two other existing multicomponent risk 
indices. Finally, we validated the model in a multicenter 
patient cohort with distinct clinical features compared to 
the derivation group.
Patients and methods
Participants
We used data from the Changi General Hospital, Singapore 
COPD Registry for this study. The registry recruited con-
secutive patients aged $40 years, who attended the specialist 
COPD clinic at Changi General Hospital between January 1, 
2008 and January 31, 2018. Diagnosis of COPD was based 
on persistent respiratory symptoms (cough, dyspnea, and 
sputum production) and supported by post-bronchodilator 
FEV
1
/FVC of ,0.7.6 We also included patients formerly clas-
sified as “GOLD 0”, who demonstrated persistent respiratory 
symptoms with emphysema or airway thickening on chest 
computed tomography, but absent airflow obstruction on 
spirometry.13 This group of patients who do not meet standard 
criteria for airway obstruction are often excluded from clini-
cal studies, despite having occult airway disease, high rate of 
exacerbation-like events, activity limitation, and frequent use 
of respiratory medications when compared to COPD patients 
diagnosed according to spirometric criteria.13 The derivation 
cohort consisted of patients with complete data on all candi-
date variables analyzed in the model derivation phase. The 
multicenter validation cohort was formed by pooling patients 
from three sources: 1) the remaining patients from the Changi 
General Hospital COPD Registry who had incomplete data 
for model derivation but sufficient data on variables in the 
final model, 2) patients from the Singapore General Hospital 
COPD clinic recruited between 1 March 2014 and 6 October 
2018 with sufficient data on variables in the final model, and 
3) the first 50 consecutive patients who presented to Tan 
Tock Seng Hospital, Singapore with a diagnosis of COPD 
in 2016. The datasets used in this analysis were deidentified 
and anonymized in accordance with personal data protection 
regulations. In addition, waiver of informed consent was 
granted by the Singhealth Centralized Institutional Review 
Board (Changi General Hospital and Singapore General 
Hospital) and National Healthcare Group Domain Specific 
Review Board (Tan Tock Seng Hospital). Informed con-
sent was waived based on ethical consideration and on the 
following grounds: the research was purely observational 
and did not interfere with patients’ usual care, the research 
could not reasonably be carried out without the use of health 
information, use of data involved no more than minimal risk 
to the research subject, and the waiver would not otherwise 
adversely affect the rights and welfare of subjects. This study 
complies with the Declaration of Helsinki.
Variables
We extracted the following variables from electronic dis-
charge summaries and outpatient consult records: demo-
graphics, anthropomorphic data, COPD Assessment Test 
(CAT) or Modified Medical Research Council dyspnea 
scale (mMRC), smoking and comorbidities (coronary artery 
disease, atrial fibrillation, heart failure, hypertension, stroke, 
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peripheral vascular disease, pulmonary hypertension, depres-
sion, anxiety, gastroesophageal reflux, peptic ulcer disease, 
gastritis, cancer, diabetes, dyslipidemia, sinonasal disease, 
asthma, obstructive sleep apnea, osteoporosis, chronic kidney 
disease, pulmonary tuberculosis [TB], and bronchiectasis). 
Comorbidities were obtained based on electronic medical 
record of International Classification of Diseases codes. 
Diagnosis of bronchiectasis was further confirmed by high-
resolution computed tomography of the thorax. Spirometry 
was performed according to American Thoracic Society/
European Respiratory Society guidelines,14 with predicted 
values obtained from Morris et al15 and adjusted by a factor 
of 0.94 as recommended for Asian patients.16 Bronchodilator 
reversibility was assessed 10–15 minutes after administration 
of 400 µg of inhaled salbutamol via a spacer.14 Results of any 
previous sputum gram-stain, aerobic culture, Ziehl–Neelsen 
stain for acid-fast bacilli and mycobacterial cultures were 
also recorded.
Hospitalized COPD exacerbation was defined according 
to consensus definition17 as primary or secondary discharge 
diagnosis of acute COPD exacerbation. All subjects had 
data on number of hospitalized exacerbations in each of the 
two consecutive years. The primary outcome was number of 
hospitalized exacerbations in the second year.
Model derivation, assessment of predictive 
accuracy, and external validation
We modeled the primary outcome using zero-inflated 
negative binomial (ZINB) regression, which is suitable for 
over-dispersed count outcome variables with excessive zeros. 
To derive the prediction model, we used a univariate-based 
method.18 Univariate ZINB regression was first performed on 
each candidate variable to identify factors associated with 
increased risk of hospitalized exacerbation. Significant 
variables arising from the univariate analysis were then 
used in multivariate ZINB regression to identify variables 
independently associated with increased risk of hospitalized 
exacerbation. Finally, we discarded variables which lost sig-
nificance in the multivariate model to form the final model.
To assess model calibration, we graphed the probability of 
observed vs predicted annual hospitalized exacerbations rate. 
Receiver operating characteristics (ROC) and area under the 
curve (AUC) analyses were used to evaluate discriminative 
predictive accuracy for the identifying high-risk patients, 
defined as experiencing $1 hospitalized exacerbation. We 
compared AUCs between our model with three other risk 
assessment methods: the GOLD risk assessment criterion 
(history of $1 exacerbation leading to hospitalization in 
the previous year); the age, dyspnea, and obstruction (ADO) 
index;19 and the dyspnea, obstruction, smoking, and exacer-
bation (DOSE) index.20
To evaluate model generalizability, we assessed calibra-
tion and discrimination in the validation cohort.
The entire dataset was used in order to maximize 
statistical power and the present analysis fulfilled rule-
of-thumb criterion of ratio of $10 outcome events 
(ie, hospitalized exacerbations) to the number of predictors 
used in the final model.
statistics
Student’s t-test, chi-squared test, or Mann–Whitney U test 
was used to compare parametric, categorical, or nonparamet-
ric data, respectively. Statistics calculations were performed 
on Stata 13 (StataCorp LP, College Station, TX, USA).
Results
A total of 237 patients from the Changi General Hospital 
COPD Registry had complete data for model derivation, and 
the remaining 169 were pooled with 200 patients from the 
Singapore General Hospital and 50 patients from Tan Tock 
Seng Hospital to form the independent validation cohort 
(N=419). Characteristics and differences between the deriva-
tion and validation cohorts are shown in Table 1. Compared 
to the validation cohort, patients in the derivation cohort were 
significantly older and had lower BMI. In addition, the deri-
vation cohort had lower use of short-acting bronchodilators 
only and higher use of triple therapy. Patients in the deriva-
tion cohort were also more likely to have a history of acute 
invasive/noninvasive ventilation, pulmonary hypertension, 
cancer, asthma, and osteoporosis than patients in the valida-
tion cohort, but prevalence of gastroesophageal reflux was 
lower than in the validation cohort. The derivation cohort 
demonstrated higher rates of long-term macrolide therapy 
compared to the validation cohort. Average prospective hos-
pitalized exacerbation rates (primary outcome) were 1.41 and 
1.04 per patient-year in the derivation and validation cohorts, 
respectively, (Mann–Whitney U test, P=0.03).
Univariate ZINB regression using data from the 
derivation cohort (Table 2) found that the following 
nontreatment variables were associated with increased 
risk of hospitalized exacerbation: number of hospitalized 
exacerbations in the previous year, previous invasive/
noninvasive ventilation, lower post-bronchodilator FEV
1
, 
CAT $10 or mMRC $2, coronary artery disease, anxiety, 
bronchiectasis, history of TB, and sputum nontuberculous 
mycobacteria (NTM) isolation. The final multivariate model, 
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Table 1 Patient characteristics
Variable Derivation cohort Validation cohort P-value (derivation vs validation cohort)
n 237 419
age, years 75±9 72±9 ,0.001
Male 222 (93.7%) 386 (92.1%) ns
ethnicity ns
Chinese 176 (74.3%) 324 (77.3%)
Malay 34 (14.3%) 53 (12.6%)
Indian 13 (5.5%) 28 (6.7%)
Caucasian 4 (1.7%) 10 (2.4%)
Others 10 (4.2%) 4 (1.0%)
BMI 20.9±5.0 21.7±4.8 0.04
Missing data 0 44
smoking status ns
never smoker 0 (0.0%) 6 (1.4%)
Current smoker 87 (36.7%) 175 (42.0%)
ex-smoker 150 (63.3%) 236 (56.6%)
Missing 0 2
hospitalizations for exacerbation in previous year 0 (0–1) 0 (0–1) ns
0 131 (55.3%) 248 (59.2%)
1 54 (22.8%) 84 (20.0%)
$2 52 (21.9%) 87 (20.8%)
Post-bronchodilator FeV1 % predicted 60±20 57±20 ns
Missing data 0 28
$80 41 (17.3%) 53 (13.6%)
50–79 111 (46.8%) 188 (48.1%)
30–49 75 (31.6%) 129 (33.0%)
,30 10 (4.2%) 21 (5.4%)
Dyspnea ns
mMrC $2 or CaT $10 209 (88.2%) 192 (82.4%)
mMrC ,2 and CaT ,10 28 (11.8%) 41 (17.6%)
Missing data 0 186
Previous acute invasive/noninvasive ventilation 89 (37.6%) 81 (19.3%) ,0.001
Comorbidities
Coronary artery disease 69 (29.1%) 108 (25.8%) ns
Atrial fibrillation 28 (11.9%) 37 (8.9%) ns
heart failure 14 (5.9%) 32 (7.6%) ns
hypertension 112 (47.3%) 191 (45.6%) ns
stroke 22 (9.3%) 40 (9.5%) ns
Peripheral vascular disease 12 (5.1%) 12 (2.9%) ns
Pulmonary hypertension 27 (11.4%) 24 (5.7%) 0.009
Depression 8 (3.4%) 18 (4.3%) ns
anxiety 4 (1.7%) 10 (2.4%) ns
Gastroesophageal reflux disease 14 (5.9%) 39 (9.3%) 0.047
Peptic ulcer disease 10 (4.2%) 18 (4.3%) ns
gastritis 21 (8.9%) 25 (6.0%) ns
Cancer 40 (16.9%) 37 (8.9%) 0.002
Diabetes 50 (21.1%) 72 (17.2%) ns
Dyslipidemia 101 (42.6%) 173 (41.3%) ns
sinonasal disease 2 (0.8%) 13 (3.1%) ns
asthma 39 (16.5%) 43 (10.3%) 0.021
Obstructive sleep apnea 6 (2.5%) 7 (1.7%) ns
Osteoporosis 22 (9.3%) 14 (3.3%) 0.001
Chronic kidney disease 17 (7.2%) 26 (6.2%) ns
history of pulmonary TB 47 (19.8%) 73 (19.8%) ns
Bronchiectasis 22 (9.3%) 36 (8.6%) ns
sputum nTM isolation 14 (5.9%) 18 (4.3%) ns
Inhaler therapy 0.015
short acting bronchodilators only 15 (6.3%) 58 (13.8%)
laBa or laMa monotherapy 44 (18.6%) 71 (16.9%)
Dual long-acting bronchodilators or ICs/laBa 67 (28.3%) 127 (30.3%)
Triple therapy 111 (46.8%) 163 (38.9%)
Macrolides 19 (8.0%) 6 (1.4%) ,0.001
Notes: Data are shown as mean ± sD, median (interquartile range), or number (%). P-values are calculated by student’s t-test, Mann–Whitney U test, or chi-squared test 
as appropriate.
Abbreviations: BMI, body mass index; CaT, COPD assessment Test; ICs, inhaled corticosteroids; laBa, long-acting beta agonist; laMa, long-acting muscarinic antagonist; 
mMRC, Modified Medical Research Council dyspnea scale; NA, not applicable; NS, not significant at P=0.05 significance level; NTM, nontuberculous mycobacteria; TB, tuberculosis.
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Table 2 Univariate ZInB regression for the primary outcome of number of hospitalized exacerbations/year
Variable Incidence rate ratio 95% CI P-value
age 0.986 0.965–1.001 ns
Female gender 0.504 0.200–1.269 ns
BMI 0.989 0.953–1.027 ns
Current smoker 1.929 0.609–1.418 ns
Previous acute invasive or noninvasive ventilation 2.064 1.385–3.078 ,0.001
number of exacerbations requiring hospitalization in the previous year 1.616 1.440–1.814 ,0.001
mMrC $2 or CaT $10 2.662 1.293–5.482 0.008
Post-bronchodilator FeV1 % predicted 0.986 0.975–0.996 0.009
Comorbidities
Coronary artery disease 1.591 1.033–2.449 0.035
Atrial fibrillation 0.900 0.475–1.705 ns
heart failure 1.456 0.636–3.332 ns
hypertension 1.228 0.819–1.842 ns
stroke 0.756 0.367–1.560 ns
Peripheral vascular disease 1.258 0.511–3.097 ns
Pulmonary hypertension 1.567 0.852–2.880 ns
Depression 2.316 0.830–6.455 ns
anxiety 4.713 1.219–18.222 0.025
Gastroesophageal reflux 0.961 0.404–2.283 ns
Peptic ulcer disease 0.993 0.362–2.728 ns
gastritis 1.854 0.952–3.610 ns
Cancer 0.708 0.405–1.240 ns
Diabetes 1.465 0.906–2.369 ns
Dyslipidemia 1.315 0.876–1.974 ns
sinonasal disease 1.424 0.170–11.932 ns
asthma 1.045 0.606–1.802 ns
Obstructive sleep apnea 0.945 0.257–3.475 ns
Osteoporosis 0.757 0.367–1.560 ns
Chronic kidney disease 1.047 0.478–2.290 ns
history of pulmonary TB 1.828 1.132–2.952 0.014
Bronchiectasis 2.638 1.416–4.915 ,0.002
sputum nTM isolation 3.140 1.481–6.657 0.003
Abbreviations: BMI, body mass index; CAT, COPD Assessment Test; mMRC, Modified Medical Research Council dyspnea scale; NS, not significant; NTM, nontuberculous 
mycobacteria; TB, tuberculosis; ZINB, zero-inflated negative binomial.
Table 3 Final multivariate ZInB regression model for the primary outcome of number of hospitalized exacerbations/year
Variable Incidence rate ratio 95% CI P-value
Previous acute invasive or noninvasive ventilation 1.60 1.15–2.22 0.005
number of exacerbations requiring hospitalization in the previous year 1.52 1.38–1.68 ,0.001
Coronary artery disease 1.90 1.36–2.66 ,0.001
Bronchiectasis 1.93 1.20–3.01 0.006
sputum nTM isolation 2.04 1.19–3.48 0.009
Abbreviations: NTM, nontuberculous mycobacteria; ZINB, zero-inflated negative binomial.
shown in Table 3, found that number of hospitalizations in 
previous year, previous invasive/noninvasive ventilation, 
coronary artery disease, bronchiectasis, and sputum NTM 
isolation were independently associated with increased risk 
of hospitalized exacerbation.
Observed and predicted annual hospitalized exacerbation 
rates for the final multivariate model were in good agreement, 
as depicted in Figure 1A. ROC curves of our model vs GOLD 
risk assessment criterion for identifying high-risk patients 
are shown in Figure 2A. Predictive accuracy of our model 
was significantly greater than using the GOLD risk assess-
ment criterion (AUC: 0.789 [95% CI: 0.732–0.846] vs AUC: 
0.690 [95% CI: 0.631–0.748], P=0.001). A subset of the 
derivation cohort, n=222, had complete data for calculating 
ADO and DOSE risk scores (Figure 3). Predictive accuracy 
of our model was higher than that for the ADO index (AUC: 
0.789 [95% CI: 0.731–0.848] vs AUC: 0.656 [95% CI: 
0.586–0.727], P=0.002). AUC of the DOSE index was 0.717 
(95% CI: 0.652–0.782), which was lower than the AUC of 
our model at borderline significance, P=0.05.
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Figure 1 Observed and predicted values for the primary outcome of annual hospitalized exacerbation rate for (A) the derivation cohort and (B) the multicenter independent 
validation cohort. Data are shown for hospitalized exacerbation rate of up to eight per year.
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Figure 2 rOC curves of our model (solid line and closed circles) and gOlD risk assessment criterion (history of $1 exacerbation leading to hospitalization in the 
previous year, dashed line and open circles) for identifying high-risk patients in (A) the derivation cohort and (B) the independent multicenter validation cohort.
Abbreviations: gOlD, global Initiative for Chronic Obstructive lung Disease; rOC, receiver operating characteristics.
Applying our multivariate model to the validation cohort, 
we again found good agreement between observed and pre-
dicted annual hospitalized exacerbation rates (Figure 1B). 
In addition, predictive accuracy for high-risk patients 
remained good and was significantly superior to the GOLD 
risk assessment criterion in the validation cohort (Figure 2B, 
AUC: 0.728 [95% CI: 0.680–0.777] vs AUC: 0.671 [95% 
CI: 0.627–0.717], P=0.01).
Discussion
In this study, our aim was to develop and externally validate 
a novel clinical prediction model for risk of hospitalized 
COPD exacerbations based on both exacerbation history and 
treatable traits. We identified several factors independently 
associated with increased prospective risk of hospitalized 
COPD exacerbation: number of hospitalized exacerbations in 
the previous year, previous invasive/noninvasive ventilation, 
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Our model
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Figure 3 rOC curves of our model, DOse index, aDO index, and gOlD risk 
assessment criterion (history of $1 exacerbation leading to hospitalization in the 
previous year) for identifying high-risk patients.
Abbreviations: aDO, age, dyspnea, and obstruction; DOse, dyspnea, obstruction, 
smoking, and exacerbation; gOlD, global Initiative for Chronic Obstructive lung 
Disease; rOC, receiver operating characteristics.
bronchiectasis, sputum NTM isolation, and coronary artery 
disease. A risk prediction model comprising these multiple 
variables demonstrated good predictive accuracy and sig-
nificantly outperformed the GOLD risk assessment criterion 
(history of $1 exacerbation leading to hospitalization in the 
previous year) and the ADO index for identifying patients at 
high-risk of hospitalized exacerbation. Predictive accuracy of 
our model was also superior to the DOSE index, but statistical 
significance was borderline (P=0.05). In addition, our model 
was capable of predicting number of hospitalized exacerba-
tions over a range of possible values, and stratified patients 
along a gradient of risk instead of two broad risk categories. 
We validated the risk prediction model in a multicenter cohort 
of COPD patients with distinct clinical characteristics and 
found that predictive accuracy remained good.
History of exacerbation is the strongest predictor of 
future exacerbations and, therefore, forms the basis for 
assessing future risk in the GOLD strategy. There are several 
multidimensional prognostic indices available for use in COPD 
patients, including for the prediction of exacerbations,21 but to 
our knowledge, no study has demonstrated that inclusion of 
other variables besides history of exacerbation leads to bet-
ter risk prediction. Motegi et al22 prospectively evaluated the 
discriminative accuracies of the ADO, DOSE, and Body mass 
index, airflow Obstruction, Dyspnea, and Exercise (BODE) 
indices for predicting exacerbations ascertained from symptom 
diaries. AUC values obtained for ADO and DOSE were similar 
to those found in the present study despite methodological dif-
ferences, but in that study, none of the indices was significantly 
better than history of exacerbation alone for predicting future 
exacerbations. ADO and DOSE were evaluated in another 
study by Jones et al using international multicenter datasets 
and found to be weak predictors of hospitalized and nonhos-
pitalized exacerbations.23 In contrast, our model demonstrated 
better discriminative accuracy for predicting hospitalized 
exacerbations than both ADO and the GOLD criterion, and a 
trend toward superior predictive accuracy compared to DOSE. 
Inclusion of comorbidities and infection, important dimensions 
known to affect exacerbation risk, is unique to our model and 
not used by other existing risk indices.
History of exacerbation,7,11,24,25 requirement for invasive/
noninvasive ventilation,26 bronchiectasis,27,28 and sputum 
NTM29,30 have all been described as independent associa-
tions of severe exacerbations. In addition, some of the sig-
nificant univariate associations such as anxiety,31 dyspnea 
ratings,11,24,32,33 and lower FEV
1
7,32 have been reported in 
other studies to predict exacerbations, although in the present 
study they became nonsignificant in the final, fully-adjusted 
model. Only a few studies have investigated whether coro-
nary artery disease is a risk factor for frequent exacerbations, 
and their results were conflicting. At least two studies did not 
find increased rate of exacerbations,34,35 although one study 
reported longer duration of exacerbation.35 Notably, studies 
on risk factors associated with exacerbations have variable 
findings. This likely reflects differences in the patient popu-
lation and risk factors studied, healthcare systems as well 
as definitions of exacerbation. An important source of vari-
ability is the inherent heterogeneity of exacerbation events, 
which may represent myriad clinicopathologic subtypes and 
mechanisms,8 each with different risk factors.
In addition to ADO, DOSE, and the GOLD criterion, 
there are several other risk prediction models for COPD 
hospitalizations or readmissions, including SCOPEX36 and 
PEARL.37 Which prediction model to use depends not only on 
predictive accuracy but also on ease of use and practicability, 
such as whether the predictor variables are available or 
routinely collected in clinical practice, and this will vary 
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depending on clinician or hospital practice patterns. Impor-
tantly, some of the variables in our full prediction model 
represent potential modifiable targets or “treatable traits”10 
for reducing hospitalized exacerbation risk. For example, 
domiciliary noninvasive ventilation has been demonstrated 
to prolong time to readmission in COPD patients with per-
sistent hypercapnia after exacerbation associated with acute 
hypercapnic respiratory failure.38 The presence of comorbid 
bronchiectasis may focus the attention of the clinician on 
treating both COPD and bronchiectasis, the latter mainly 
aimed at airway secretion clearance and treating acute or 
chronic airway infections.39 There is insufficient evidence 
to guide the management of patients with COPD-bronchiec-
tasis overlap. However, COPD-bronchiectasis overlap may 
influence the selection of therapies, including avoidance of 
inhaled corticosteroids, or use of long-term macrolides which 
have efficacy in reducing exacerbations in both COPD40 and 
bronchiectasis.41 Similarly, NTM lung disease represents a 
treatable pulmonary infection, although treatment of NTM 
in the context of COPD has not been studied. The armamen-
tarium of interventions for coronary artery disease is wide 
and includes coronary revascularization, antiplatelet therapy, 
beta-blockers, statins, and angiotensin-converting enzyme 
inhibitors. Evidence from observational studies indicate that 
beta-blockers may have a beneficial effect on reducing COPD 
exacerbations in patients with coronary artery disease.42–44
The strengths of our study are: use of a real-world 
nonclinical trial COPD patient population with significant 
comorbidities and overlap with other respiratory diseases, 
and external validation in a multicenter cohort with several 
significantly different characteristics compared to the deri-
vation cohort. In addition, bronchiectasis was diagnosed by 
computed tomography, which is the gold standard. There are 
several important limitations. First, although the prediction 
model was validated in other hospitals, the wider general-
izability of the prediction model remains unassessed. The 
study was conducted in Singapore and applicability in other 
countries may be limited due to different underlying disease 
processes and prevalence of comorbidities. Thus, the risk 
prediction model needs to be prospectively evaluated and 
further validated in other countries and healthcare settings. 
Second, the model does not include biomarkers such as 
blood eosinophils and fibrinogen which are known to predict 
exacerbations and hospitalizations,45 and should be a focus 
of future research. Third, clinical utility and impact of the 
model has not been evaluated. For example, estimating a 
patient’s risk using our prediction model would require a 
risk calculator, and some of the variables in the model may 
not be available in primary care, eg, computed tomography 
diagnosis of bronchiectasis or sputum cultures, thereby lim-
iting usefulness of the risk prediction model in the primary 
care setting. Whether the risk prediction model will result 
in meaningful improvements in patient outcomes, care pro-
cesses, or cost has not been evaluated. Fourth, we focused 
exclusively on severe exacerbations requiring hospitalization 
and did not have data on mild or moderate exacerbations 
not leading to hospitalization, which may impact on effect 
size of the incident rate ratios obtained here.46 Nevertheless, 
ascertainment from primary hospital discharge diagnosis 
of COPD exacerbation is objective and widely accepted,17 
and could be reliably assessed using our electronic medical 
records-based methodology.
Conclusion
To conclude, we have derived and validated a novel risk 
prediction model based on history of exacerbation and other 
“treatable traits” which are known to contribute to exacerba-
tion risk. Our model outperforms several other existing risk 
indices and is capable of stratifying patients along a gradient 
of risk. Future studies should aim to assess whether using 
this prediction model to target treatable traits has any clinical 
utility in preventing COPD exacerbations. Further impact 
analysis is also needed to investigate if implementation of 
our risk prediction model is better than usual care for the 
patient, care processes or cost outcomes.
Acknowledgments
The authors would like to thank Mr Gerald Sim and Changi 
General Hospital Clinical Trials Research Unit for their 
assistance in conducting this study. The abstract of this paper 
was presented at Asian Pacific Society of Respirology 2018 
Congress as a poster presentation with interim findings. The 
poster’s abstract was published in “Poster Abstracts” in Res-
pirology: https://onlinelibrary.wiley.com/doi/full/10.1111/
resp.13420_131.
Disclosure
AA received grants and/or personal fees from GlaxoSmith-
Kline, AstraZeneca, Novartis, and Boehringer Ingelheim. 
PYT is supported by Singapore Ministry of Health National 
Medical Research Council under its Research Training Fel-
lowship (NMRC/Fellowship/0049/2017). The other authors 
report no conflicts of interest in this work.
References
1. Dalal A, Christensen L, Liu F, Riedel AA. Direct costs of chronic 
obstructive pulmonary disease among managed care patients. Int J Chron 
Obstruct Pulmon Dis. 2010;5:341–349.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
20
0 
on
 2
2-
M
ay
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2019:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
727
Yii et al
 2. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzi-
cha JA. Effect of exacerbation on quality of life in patients with chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 
157(5 Pt 1):1418–1422.
 3. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality 
of life in patients with chronic obstructive pulmonary disease: a 2 year 
follow up study. Thorax. 2004;59(5):387–395.
 4. Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute exacerbations 
and lung function loss in smokers with and without chronic obstructive 
pulmonary disease. Am J Respir Crit Care Med. 2017;195(3):330.
 5. Suissa S, dell’aniello S, Ernst P. Long-term natural history of chronic 
obstructive pulmonary disease: severe exacerbations and mortality. 
Thorax. 2012;67(11):957–963.
 6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). GOLD 
2018 global strategy for the diagnosis, management, and prevention of 
chronic obstructive lung disease 2018 report. 2018.
 7. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in 
chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12): 
1128–1138.
 8. Bafadhel M, Mckenna S, Terry S, et al. Acute exacerbations of chronic 
obstructive pulmonary disease: identification of biologic clusters and 
their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671.
 9. Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev. 
2018;27(147):170103.
 10. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward preci-
sion medicine of chronic airway diseases. Eur Respir J. 2016;47(2): 
410–419.
 11. Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations 
in patients with chronic obstructive pulmonary disease: an analysis of 
the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626.
 12. Le Rouzic O, Roche N, Cortot AB, et al. Defining the “Frequent Exac-
erbator” phenotype in COPD: a hypothesis-free approach. Chest. 2018; 
153(5):1106–1115.
 13. Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of 
symptoms in smokers with preserved pulmonary function. N Engl J 
Med. 2016;374(19):1811–1821.
 14. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of 
spirometry. Eur Respir J. 2005;26(2):319–338.
 15. Morris JF, Koski A, Johnson LC. Spirometric standards for healthy 
nonsmoking adults. Am Rev Respir Dis. 1971;103(1):57–67.
 16. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for 
lung function tests. Eur Respir J. 2005;26(5):948–968.
 17. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifica-
tions. Eur Respir J Suppl. 2003;41:46s–53s.
 18. Adams ST, Leveson SH. Clinical prediction rules. BMJ. 2012;344:d8312.
 19. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the 
prognostic assessment of patients with chronic obstructive pulmonary 
disease: the updated bode index and the ado index. The Lancet. 2009; 
374(9691):704–711.
 20. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and valida-
tion of a composite index of severity in chronic obstructive pulmonary 
disease: the dose index. Am J Respir Crit Care Med. 2009;180(12): 
1189–1195.
 21. Dijk WD, Bemt L, Haak-Rongen S, et al. Multidimensional prognostic 
indices for use in COPD patient care. A systematic review. Respir Res. 
2011;12(1):151.
 22. Motegi T, Jones RC, Ishii T, et al. A comparison of three multidimen-
sional indices of COPD severity as predictors of future exacerbations. 
Int J Chron Obstruct Pulmon Dis. 2013;8:259–271.
 23. Jones RC, Price D, Chavannes NH, et al. Multi-component assessment 
of chronic obstructive pulmonary disease: an evaluation of the ado 
and dose indices and the global obstructive lung disease categories in 
international Primary care data sets. NPJ Prim Care Respir Med. 2016; 
26(1):16010.
 24. Montserrat-Capdevila J, Godoy P, Marsal JR, Barbé F, Galván L. Risk 
factors for exacerbation in chronic obstructive pulmonary disease: 
a prospective study. Int J Tuberc Lung Dis. 2016;20(3):389–395.
 25. Müllerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations 
of COPD. Chest. 2015;147(4):999–1007.
 26. Chu CM, Chan VL, Lin AW, Wong IW, Leung WS, Lai CK. Readmis-
sion rates and life threatening events in COPD survivors treated with 
non-invasive ventilation for acute hypercapnic respiratory failure. 
Thorax. 2004;59(12):1020–1025.
 27. Minov J, Stoleski S, Mijakoski D, Vasilevska K, Atanasovska A. 
Exacerbations in COPD patients with bronchiectasis. Medical Sciences. 
2017;5(2):7.
 28. Ni Y, Shi G, Yu Y, Hao J, Chen T, Song H. Clinical characteristics of 
patients with chronic obstructive pulmonary disease with comorbid 
bronchiectasis: a systemic review and meta-analysis. Int J Chron 
Obstruct Pulmon Dis. 2015;10:1465–1475.
 29. Diel R, Jacob J, Lampenius N, et al. Burden of non-tuberculous myco-
bacterial pulmonary disease in Germany. Eur Respir J. 2017;49(4): 
1602109.
 30. Huang CT, Tsai YJ, Wu HD, et al. Impact of non-tuberculous mycobac-
teria on pulmonary function decline in chronic obstructive pulmonary 
disease. Int J Tuberc Lung Dis. 2012;16(4):539–545.
 31. Pooler A, Beech R. Examining the relationship between anxiety and 
depression and exacerbations of COPD which result in hospital admis-
sion: a systematic review. Int J Chron Obstruct Pulmon Dis. 2014;9: 
315–330.
 32. Mcgarvey L, Lee AJ, Roberts J, Gruffydd-Jones K, Mcknight E, 
Haughney J. Characterisation of the frequent exacerbator phenotype 
in COPD patients in a large UK primary care population. Respir Med. 
2015;109(2):228–237.
 33. Wan ES, Demeo DL, Hersh CP, et al. Clinical predictors of frequent 
exacerbations in subjects with severe chronic obstructive pulmonary 
disease (COPD). Respir Med. 2011;105(4):588–594.
 34. Jones PW, Mullerova H, Agusti A, et al. Cardiovascular disease does not 
predict exacerbation rate or mortality in chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med. 2018;197(3):400–403.
 35. Patel ARC, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The 
impact of ischemic heart disease on symptoms, health status, and 
exacerbations in patients with COPD. Chest. 2012;141(4):851–857.
 36. Make BJ, Eriksson G, Calverley PM, et al. A score to predict short-term 
risk of COPD exacerbations (SCOPEX). Int J Chron Obstruct Pulmon Dis. 
2015;10:201–209.
 37. Echevarria C, Steer J, Heslop-Marshall K, et al. The pearl Score predicts 
90-day readmission or death after hospitalisation for acute exacerbation 
of COPD. Thorax. 2017;72(8):686–693.
 38. Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive 
ventilation with oxygen therapy vs oxygen therapy alone on hospital 
readmission or death after an acute COPD exacerbation. JAMA. 2017; 
317(21):2177–2186.
 39. Polverino E, Goeminne PC, Mcdonnell MJ, et al. European Respira-
tory Society guidelines for the management of adult bronchiectasis. 
Eur Respir J. 2017;50(3):1700629.
 40. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention 
of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698.
 41. Kelly C, Chalmers JD, Crossingham I, et al. Macrolide antibiotics for 
bronchiectasis. Cochrane Database Syst Rev. 2018;3:CD012406.
 42. Bhatt SP, Wells JM, Kinney GL, et al. β-Blockers are associated with 
a reduction in COPD exacerbations. Thorax. 2016;71(1):8–14.
 43. du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of 
mortality and exacerbation in patients with COPD: a meta-analysis of 
observational studies. PLoS One. 2014;9(11):e113048.
 44. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers 
may reduce mortality and risk of exacerbations in patients with chronic 
obstructive pulmonary disease. Arch Intern Med. 2010;170(10): 
880–887.
 45. Couillard S, Larivée P, Courteau J, Vanasse A. Eosinophils in COPD 
exacerbations are associated with increased readmissions. Chest. 2017; 
151(2):366–373.
 46. Effing TW, Kerstjens HAM, Monninkhof EM, et al. Definitions of 
exacerbations. Chest. 2009;136(3):918–923.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
20
0 
on
 2
2-
M
ay
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
The International Journal of COPD is an international, peer-reviewed 
journal of therapeutics and pharmacology focusing on concise rapid 
reporting of clinical studies and reviews in COPD. Special focus is given 
to the pathophysiological processes underlying the disease, intervention 
programs, patient focused education, and self management protocols. 
This journal is indexed on PubMed Central, MedLine and CAS. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
International Journal of COPD 2019:14submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
728
Yii et al
Point your SmartPhone at the code above. If you have a  
QR code reader the video abstract will appear. Or use:
http://youtu.be/j7M1OCXu8IM
Video abstract
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
20
0 
on
 2
2-
M
ay
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
